C&R Research Inc. (KOSDAQ:359090)

South Korea flag South Korea · Delayed Price · Currency is KRW
900.00
0.00 (0.00%)
At close: Feb 19, 2026
Market Cap51.55B -21.8%
Revenue (ttm)63.97B +4.5%
Net Income2.80B -53.6%
EPS49.15 -53.2%
Shares Out57.47M
PE Ratio18.25
Forward PEn/a
Dividend10.00 (1.11%)
Ex-Dividend DateDec 29, 2025
Volume161,960
Average Volume224,788
Open890.00
Previous Closen/a
Day's Range887.00 - 910.00
52-Week Range805.00 - 1,216.00
Beta0.05
RSI52.40
Earnings DateFeb 11, 2026

About C&R Research

C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company’s therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea. [Read more]

Industry Commercial Physical and Biological Research
Founded 1997
Employees 510
Stock Exchange KOSDAQ
Ticker Symbol 359090
Full Company Profile

Financial Performance

In 2024, C&R Research's revenue was 59.69 billion, an increase of 8.32% compared to the previous year's 55.10 billion. Earnings were 3.84 billion, a decrease of -30.99%.

Financial Statements